Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth

Abstract Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment strategy with high response rates in myeloma. However, durable cures following anti-BCMA CAR-T cell treatment of myeloma are rare. One potential r...

Full description

Bibliographic Details
Main Authors: Fumou Sun, Yan Cheng, Visanu Wanchai, Wancheng Guo, David Mery, Hongwei Xu, Dongzheng Gai, Eric Siegel, Clyde Bailey, Cody Ashby, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Yupo Ma, Qing Yi, Robert Z. Orlowski, Maurizio Zangari, Frits van Rhee, Siegfried Janz, Gail Bishop, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-44873-4

Internet

https://doi.org/10.1038/s41467-024-44873-4

Similar Items